Clinical Trial Update: Flupirtine as Oral Treatment in Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Flupirtine as an oral treatment for Relapsing-Remitting Multiple Sclerosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Flupirtine (flupirtine)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: TERMINATED